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What’s new? 
 Gestational diabetes is associated with pre-pregnancy obesity and excessive 
gestational weight gain. 
 However, there is no clear evidence to guide weight management after diagnosis of 
gestational diabetes (at 28 weeks).  
 In this study, excessive gestational weight gain was strongly associated with fetal 
growth and difficult deliveries in women with gestational diabetes.  
 Women who gained weight after diagnosis needed higher insulin doses and had 
higher postnatal glucose concentrations. 
 Keeping weight stable after diagnosis of gestational diabetes should be a priority to 
improve outcomes for both mother and child; 28 weeks is not too late to offer advice 
or intervention. 
 A clinical trial to guide weight management in women with gestational diabetes 
would be extremely useful to confirm these findings and provide clear targets for 
weight gain after diagnosis.  
 
Abstract 
Aim Excessive gestational weight gain increases risk of gestational diabetes mellitus (GDM) 
but it remains unclear whether weight control after GDM diagnosis improves outcomes. We 
assessed whether: (1) total gestational weight gain during pregnancy (0–36 weeks); (2) early 
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gestational weight gain (0–28 weeks, before GDM diagnosis); or (3) late gestational weight 
gain (28–36 weeks, after diagnosis) are associated with maternal–fetal outcomes. 
 
Methods Some 546 women with GDM who delivered viable singleton infants at a single UK 
obstetric centre (October 2014 to March 2017) were included in this retrospective 
observational study. 
 
Results Higher total gestational weight gain was associated with Caesarean section [n = 376; 
odds ratio (OR) 1.05; confidence intervals (CI) 1.02–1.08, P < 0.001] and large for 
gestational age (OR 1.08; CI 1.03–1.12, P < 0.001).  Higher late gestational  weight gain (28–
36 weeks; n = 144) was associated with large for gestational age (OR 1.17; CI 1.01–1.37, 
P < 0.05), instrumental deliveries (OR 1.26; CI 1.03–1.55, P < 0.01), higher total daily 
insulin doses (36 weeks; beta coefficient 4.37; CI 1.92–6.82, P < 0.001), and higher post-
partum 2-h oral glucose tolerance test  concentrations (beta coefficient 0.12; CI 0.01–0.22, 
P < 0.05). Women who avoided substantial weight gain after GDM diagnosis had 0.7 mmol/l 
lower postnatal 2-h glucose and needed half the amount of insulin/day at 36 weeks compared 
with women with substantial weight gain after diagnosis. There were no significant 
associations between early gestational weight gain (0–28 weeks) and pregnancy outcomes. 
Conclusions These findings suggest that controlling gestational weight gain should be a 
priority following GDM diagnosis to optimize pregnancy outcomes and improve maternal 
postnatal glucose homeostasis.  The period after diagnosis of GDM (often 28 weeks 
gestation) is not too late to offer lifestyle advice or intervention to improve weight 
management and pregnancy outcomes.  
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<H1>Introduction 
Gestational diabetes mellitus (GDM) is defined as hyperglycaemia with first onset or 
recognition in pregnancy and is associated with a range of maternal–fetal complications 
including Caesarean delivery and an increased risk of large for gestational age (LGA; > 90th 
percentile) infants [1,2]. GDM occurs more commonly in women who are overweight or 
obese prior to pregnancy, and in those with excessive gestational weight gain [3,4]. Despite 
the importance of weight in the aetiology of GDM, it remains unclear if women with GDM 
can benefit from limiting gestational weight gain. 
 
Excessive gestational weight gain in normoglycaemic pregnancies can contribute to poor 
outcomes for both mother and child. Women with excessive gestational weight gain are at 
higher risk of hypertensive disorders [5], LGA [6], macrosomia [7] depression [8], and 
developing Type 2 diabetes and cardiometabolic disease in later life [9]. Infants exposed to 
excess gestational weight gain in utero have increased body weight, increased fat mass and 
increased blood pressure in childhood [10–12]. However, weight control in pregnancy is 
controversial, and concerns have been raised about safety [13]. 
 
Despite these concerns, for women with GDM (a weight-related comorbidity), weight control 
might feasibly improve metabolic health and reduce pregnancy complications [13–15]. 
Recent work demonstrates that strategies to limit gestational weight gain within the context 
of GDM can be safe, feasible and acceptable to women [16]. 
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The aim of this study was to assess whether total gestational weight gain (0–36 weeks) is 
associated with pregnancy outcomes in women with GDM. Because many women are not 
diagnosed with GDM until 28 weeks, we also assessed whether early (0–28 weeks) or late 
(28–36 weeks) weight gain is associated with pregnancy outcomes. 
 
<H1>Methods 
<H2>Population and standard care 
Women with a diagnosis of GDM who delivered a singleton infant at a viable gestation 
(≥ 24 weeks) at the Cambridge Universities NHS Foundation Trust between October 2014 
and March 2017 were included in this retrospective observational study. The study was 
approved as a service evaluation, and our Institutional Review Board granted approval for 
further analysis of the data for research purposes. Because our hospital uses a paperless 
system (Epic E-hospital system), women were identified using searches of the electronic 
hospital records. The accuracy of the diagnosis and treatment information was confirmed for 
a selection of cases by hand-searching each record individually. Where women had several 
eligible pregnancies during the period of data collection, only the first eligible pregnancy was 
included. 
 
Maternal weight and height were measured at antenatal booking in the community. Pre-
pregnancy BMI was based upon measured weight at antenatal booking (8–12 weeks). In the 
small percentage (~ 2%) of cases where no booking weight was recorded, self-reported pre-
pregnancy weight was used.  Following a diagnosis of GDM, women were weighed 
fortnightly at the diabetes in pregnancy clinic using the same set of scales, which are 
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regularly calibrated (Seca, Birmingham, UK). Maternal weights recorded within < 1 week of 
our defined 28- and 36-week time-points were included in the analysis.  
 
<H2>Detection of GDM 
During the time of data collection, all pregnant women were invited for screening using 
random plasma glucose (typically 12–16 weeks’ gestation) at antenatal booking. Women with 
a random plasma glucose  > 7.0 mmol/l or a previous diagnosis of GDM were offered a 75-g 
oral glucose tolerance test (OGTT) within 1 week of booking. All women without known 
GDM/pre-existing diabetes were screened at 24–28 weeks with a 50-g glucose challenge test: 
women with a glucose challenge test result > 7.7 mmol/l were then referred for a 75-g OGTT 
[17,18]. Additional OGTTs were performed in later pregnancy on an ad hoc basis where 
indicated clinically. Women with known pre-existing diabetes were excluded. The diagnostic 
criteria for GDM were based upon the criteria of the International Association of the Diabetes 
in Pregnancy Study Groups (IADPSG) with a slightly higher fasting threshold (75-g OGTT 
0 h ≥ 5.3 mmol/l; 1 h ≥ 10.0 mmol/l; 2 h ≥ 8.5 mmol/l). On average, 15% of our antenatal 
population have an OGTT and the overall prevalence of GDM is ~ 5%[19] 
 
Following diagnosis, women with GDM were seen every 2–4 weeks at a multidisciplinary 
clinic (joint obstetrics, diabetes specialist nurse, physician, dietician and midwife), 
encouraged to monitor their blood glucose levels at least four times daily (fasting and 1-h 
post breakfast, lunch and dinner). As per the standard care pathway in our institution, women 
with a new diagnosis of GDM received individual dietary advice and were advised to follow 
a low glycaemic index diet and avoid excessive weight gain for the remainder of pregnancy. 
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Women with hyperglycaemia despite dietary modification received metformin or insulin 
treatment according to the guidelines of the National Institute for Health and Care Excellence 
(NICE) [20]. The decision to start metformin rather than insulin was based upon patient 
choice following advice from their physician. Women who did not achieve the NICE 
glycaemic control targets with metformin alone were advised to start insulin. Many of these 
women continued to take metformin, if it had shown some efficacy and was not associa ted 
with side effects. All treatments being received at 36 weeks’ gestation were recorded and 
used in the analysis. All women diagnosed with GDM were offered a post-partum OGTT at 
6–8 weeks following delivery. 
 
<H2>Laboratory analysis 
For the OGTT, venous blood was collected using fluoride–oxalate tubes and analysed using a 
hexokinase method (Dimension RXL MAX Clinical Chemistry System, Siemens Healthcare 
Diagnostics, Deerfield, IL, USA) in our accredited laboratory (Clinical Pathology 
Accreditation, UK). 
 
<H2>Definitions 
Total gestational weight gain was defined as weight change in kilograms between pre-
pregnancy/booking weight and weight at 36 weeks (0–36 weeks). Early gestational weight 
gain was defined as weight gain between the pre-pregnancy/booking weight and 28 weeks 
(0–28 weeks). Late gestational weight gain occurred between 28 and 36 weeks. Infants born 
before 36 weeks were not included in the analysis of total or late gestational weight gain. 
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LGA and small for gestational age (SGA) were defined as birthweight > 90th and < 10th 
percentile for gestational age respectively. These outcomes were defined using population-
specific z-scores with adjustment for estimated gestational age at birth and for the sex of the 
baby. 
 
Post-partum glucose tolerance was measured using a 75-g OGTT at 6–8 weeks following 
delivery. 
 
<H2>Statistical analysis 
Data were collected for demographic information, maternal weight, glucose screening results 
and pregnancy outcomes. Participant characteristics are presented as n (%) for categorical 
data and mean (IQR) for continuous data. We did not impute missing data. 
 
Where possible, data were analysed as continuous variables to avoid categorization of 
quantitative data. Gestational weight gain was assessed using both the Institute of Medicine 
(IOM) guidelines and as a percentage gain from baseline or pre-pregnancy weight [22]. 
 
Associations between antenatal characteristics, pregnancy outcomes and gestational weight 
gain were assessed using multivariate logistic regression and results are presented as odds 
ratios (95% confidence intervals). Findings were considered statistically significant at an 
alpha level of 0.05.  Statistical analysis was performed using STATA® (version 12.0; 
StataCorp, College Station, TX, USA) or the R statistical software package version 2.14.1. 
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Possible confounders were identified for all outcomes based on the literature and by 
assessment of other variables.  For each measurement, the strongest two to four independent 
confounders were included as an adjustment, provided they were potentially on the causative 
pathway. 
 
Some 546 pregnancies were identified which met the inclusion criteria; 417 pregnancies had 
information available on pre-pregnancy weight or booking weight. Data on weight at 28 and 
36 weeks were available for 159 and 456 pregnancies, respectively. Total gestational weight 
gain, early gestational weight gain and late gestational weight gain could be calculated in 
376, 129 and 144 pregnancies, respectively (Fig. 1). Assessment of missing data shows that 
data were missing at random. Some 120 individuals had data available for calculation of total, 
early and late gestational weight gain.  
 
Odds ratios were adjusted for pre-pregnancy BMI and antenatal glucose concentrations. 
Models relating to fetal growth (LGA and SGA) were also adjusted for parity, which was 
independently associated with fetal growth outcomes. Further adjustments, for example, for 
maternal age, did not substantially affect these analyses. Models relating to delivery mode 
(vaginal delivery, Caesarean section and instrumental delivery) were also adjusted for 
birthweight z-score which takes account of gestational age at birth and infant gender.  
<H1>Results 
Baseline characteristics of the study population are shown in Table 1. Not all women had data 
available for each time point (Fig. 1). Mean maternal weights at 0, 28 and 36 weeks were 
76.8 (62.0–88.9) kg, 88.9 (72.1–102.6) kg and 89.6 (72.8–101.8) kg, respectively. Total 
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gestational weight gain was negatively associated with pre-pregnancy BMI (beta coefficient 
−0.79; CI −0.89 to −0.68, P < 0.001) and positively associated with infant birthweight z-score 
(adjusted for sex and gestation, beta coefficient 0.02; CI 0.01 to 0.04, P < 0.001). 
 
<H2>Effect of gestational weight gain upon pregnancy outcomes 
The effect of total gestational weight gain, early gestational weight gain and late gestational 
weight gain (expressed as a percentage change from pre-pregnancy weight) on pregnancy 
outcomes and treatment requirements are shown in Table 2. Total gestational weight gain was 
strongly associated with fetal growth, both positively with LGA (P < 0.001) and negatively 
with SGA (P < 0.05). Increased total gestational weight gain increased the likelihood of 
Caesarean delivery (P < 0.01) and reduced the likelihood of spontaneous vertex (vaginal) 
delivery (SVD) (P < 0.001). Although early gestational weight gain is considered important 
for the development of GDM, it was not associated with any of the studied pregnancy 
outcomes. Late gestational weight gain was associated with increased odds of LGA 
(P < 0.05) and instrumental delivery (P < 0.01). Women with higher degrees of late 
gestational weight gain had higher postnatal glucose concentrations (P < 0.05 for both fasting 
and 2-h OGTT glucose concentrations). However, the absolute difference in fasting 
concentrations was relatively small (0.1 mmol/l). The difference was more marked with 
postnatal 2-h OGTT glucose concentrations, of 5.4 mmol/l (97 mg/dl) for women in the first 
tertile of late gestational weight gain (n = 47) and 6.1 mmol/l (110 mg/dl) for women in the 
third tertile (n=50). 
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<H2>The effects of treatment 
The use of metformin and insulin were considered potential confounders in the assessment of 
outcomes such as LGA, SGA and delivery modality. Although metformin was related to 
gestational weight gain, its effects were entirely removed by adjustment for pre-pregnancy 
BMI, suggesting that in this study, metformin tended to be used for women with a higher pre-
pregnancy BMI (who tend to have lower amounts of gestational weight gain overall). Growth 
and delivery outcomes were adjusted for pre-pregnancy BMI and further adjustment for 
metformin use did not alter the effects.  
 
The use of insulin (as a categorical variable) was not associated with total, early or late 
gestational weight gain, and adjustment for insulin use did not affect growth or delivery 
outcomes. Total insulin dose was related to late GWG but defining a causal relationship here 
is not straightforward. Undoubtedly, insulin can make women gain weight, but increased 
weight gain may increase blood glucose and increase treatment requirements. Furthermore, 
this relationship was skewed by outliers among our data. We therefore adjusted for antenatal 
glucose concentrations (measurement at time 0 in the diagnostic OGTT) rather than for 
insulin dosage. Late gestational weight gain was associated with requiring higher total daily 
doses of insulin (P < 0.05), affecting both short-acting (novorapid; P < 0.05) and long-acting 
(insulatard; P < 0.001) insulin doses.  Insulin-requiring women in the first tertile of late 
gestational weight gain (n = 25) required on average 18 units of insulin per day at 36 weeks, 
whereas those in the third tertile (n = 25) required 41 units. 
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<H2>Classification of gestational weight gain 
Gestational weight gain was categorized in two ways: percentage gestational weight gain 
from pre-pregnancy weight and adherence to the IOM guidelines [22] (Tables 3 and 4a). 
Pregnancy outcomes categorized according to percentage gestational weight gain were 
assessed over three subgroups (< 5%, 5–15% and > 15% of pre-pregnancy weight gained) 
(Table 3). Compared with women who gained 5–15% body weight, women with < 5% 
gestational weight gain had a lower likelihood of delivery by Caesarean section (P < 0.01), 
increased likelihood of SVD (P < 0.01) and no significant change in the rate of LGA (5%) or 
SGA (10%). Compared with women who gained 5–15% body weight, women who gained 
> 15% body weight had a lower likelihood of SVD (P < 0.05) and a higher likelihood of 
delivery by Caesarean section (P < 0.05) with an increased risk of LGA (P < 0.05). 
 
Women were reclassified according to whether they had gained under, according to, or above 
the IOM recommendations for pregnancy weight gain, specific to their pre-
pregnancy/booking BMI category (Table 4a). Of the 375 women included in this analysis, 
29.6% gained weight within recommended limits, whereas 44.5% and 25.9% gained below or 
above the recommended limits respectively. For women who gained below the IOM 
recommendations, there was an almost sevenfold increase in the risk of SGA (P < 0.01), 
resulting in an SGA rate of 11% (LGA rate 6%). In comparison, women who gained weight 
within IOM recommended targets had 2% SGA and 11% LGA and those with excessive 
gestational weight gain above the IOM recommendations had 7% SGA and 18% LGA.  
Women who gained weight above recommended limits had an increased likelihood of 
delivery by Caesarean section (P < 0.05) and a decreased likelihood of SVD (P < 0.05) 
compared with those who gained weight within recommended limits. 
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The IOM recommendations also suggest that all women should gain at least 5 kg during 
pregnancy (Table 4b). Further analysis was performed to identify if GWG < 5 kg is 
associated with an excess of adverse outcomes in this cohort of women with established 
GDM. Gestational weight gain < 5 kg was associated with a lower likelihood of delivery by 
Caesarean section (P < 0.05) and a higher chance of SVD (P < 0.05). There was a lower 
likelihood of LGA (P < 0.01), but also a trend towards an increased likelihood of SGA 
(P = 0.07) resulting in an SGA rate of 9% and an LGA rate of 4%. When birthweight was 
analysed as a continuous variable, there was a significant association between GWG < 5 kg 
and lower birthweight (P < 0.01). There was no association between gestational weight gain 
< 5 kg and the need for insulin treatment for GDM or postnatal fasting glucose.  
 
<H1>Discussion 
This study demonstrates that gestational weight gain has significant associations with fetal 
growth, delivery modality and insulin requirements during pregnancy. Late gestational 
weight gain (after 28 weeks) is also associated with post-partum glucose concentrations. 
These findings suggest that control of gestational weight gain should be a priority following a 
diagnosis of GDM, for optimizing maternal and fetal outcomes, and that 28 weeks’ gestation 
is not too late to offer lifestyle advice or intervention.  
 
Our findings are consistent with other reports demonstrating that total gestational weight gain 
in women with GDM is associated with LGA [8, 23]. However, in clinical practice, many 
women already have excessive gestational weight gain at the time of GDM diagnosis, raising 
the concern that the appropriate window for intervention to control weight gain has passed. 
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This study suggests that intervening to control gestational weight gain even after GDM 
diagnosis could improve outcomes resulting in reduced LGA rates, reduced maternal insulin 
doses, decreased Caesarean sections, and improved maternal post-partum glucose tolerance. 
In fact, per kilogram of weight gained, late gestational weight gain appeared to have a larger 
effect upon rates of LGA, compared with total gestational weight gain. Control of gestational 
weight gain in the context of GDM has the potential to improve women’s health in both the 
long and the short term. However, clinical behaviour change is notoriously difficult to 
achieve and trials of diet and exercise interventions to limit gestational weight gain in women 
at risk of GDM have achieved modest benefits overall [23–26]. One recent study by Hodson 
and colleagues [16] demonstrated that limiting gestational weight gain using a low-calorie 
diet in GDM is feasible and acceptable to women when good support from the 
multidisciplinary healthcare team is provided.  
 
This retrospective observational study used clinical data from a single large tertiary referral 
centre to identify associations between gestational weight gain and pregnancy outcomes in 
women with GDM. The use of a single centre provides consistency in the screening and 
identification of women with GDM and in the advice and treatment given to women after 
diagnosis. Throughout the study, the protocols for initiation of GDM treatment, dose titration 
and delivery planning were delivered by a single clinical team, which minimizes 
unintentional variation within the cohort. Although not all women had data available for 
weight at all time-points, analysis suggests that weights are missing at random among the 
GDM population. The sample size and the well characterized nature of our cohort are 
sufficient to draw useful conclusions, but of course do not replace the need for robust 
prospective studies in this field. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
 
Rates of LGA were low overall in this study (10.4%), with relatively low levels of gestational 
weight gain following diagnosis of GDM. The reasons for this are unclear but may be a result 
of advice to avoid excessive weight gain during the last trimester of pregnancy given to 
women in our centre following GDM diagnosis.  As described previously [27], our population 
is predominantly white (89%) with relatively low levels of ethnic diversity (5% Asian, < 2% 
Black), which may limit the applicability of our findings to other populations. However, 
gestational weight gain has previously been shown to be related to pregnancy outcomes in 
many different ethnic groups [28]. 
 
Excessive gestational weight gain is currently defined for healthy, non-diabetic women using 
the IOM guidelines (2009) based upon a woman’s pre-pregnancy BMI [29]. However, many 
pregnant women exceed these targets and have excessive weight gain, particularly in the 
context of GDM. There are currently no specific thresholds to guide weight management in 
GDM. The guideline from NICE regarding women with diabetes in pregnancy highlights the 
importance of pre-pregnancy and post-partum weight control but does not mention 
gestational weight gain [20]. The American Diabetes Association supports ‘weight 
management’ as part of standard medical care for women with GDM, referring to the IOM 
2009 guidelines [29,30]. Our results suggest that calculating appropriate gestational weight 
gain based on a percentage of pre-pregnancy BMI might help to identify more women at risk 
of adverse outcomes than absolute weight gain standards. However, further work is needed to 
identify which targets are most appropriate for women with GDM, who are already at higher 
risk of pregnancy complications compared with women with normal glucose tolerance during 
pregnancy. 
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Although the association between maternal weight and pregnancy outcomes is well 
established, it remains unclear exactly how excessive gestational weight gain might affect the 
fetus. One possibility is that excessive gestational weight gain causes a deterioration in 
maternal glycaemia which promotes fetal growth and predisposes to more medical 
interventions around delivery. The current study supports this hypothesis as treatment 
requirement were higher in women with higher gestational weight gain. However, it is also 
possible that excessive gestational weight gain reflects a maternal diet rich in calorie-dense 
foods, such as sugar and fat, which in turn promotes excessive fetal growth.  
 
The current study suggests that a kilogram of weight gained in the latter part of pregnancy 
has a larger effect upon fetal growth than weight gain earlier in pregnancy. This may be 
because the fetal growth rate is highest in late pregnancy, and a factor such as weight gain 
which accelerates that growth might have an exponential effect, particularly if it is associated 
with higher glycaemia and higher insulin doses. Conversely, it may be that weight gained 
after the diagnosis of GDM has more metabolic influence, while women earlier in pregnancy 
have less metabolic consequences of weight gain prior to developing GDM.  
 
Although LGA remains a particular concern in offspring of women with GDM, inadequate 
gestational weight gain also carries the risk of poor fetal growth. SGA rates are generally low 
in infants born to mothers with GDM, which makes this issue particularly difficult to study in 
depth. SGA has been associated with both inadequate and excessive maternal weight in 
previous work [31,32]. In this study, SGA rates were significantly increased in women with 
gestational weight gain below the IOM thresholds but also non-significantly increased in 
women with excessive gestational weight gain (Table 4a). This suggests that women who 
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attain an appropriate level of gestational weight gain may reduce the risk of both LGA and 
SGA to their infants. Further work is needed to clarify the relationship between SGA and 
weight changes in pregnancy and how this might vary in women with GDM. Our work 
suggests that controlling, but not severely restricting, gestational weight gain after GDM 
diagnosis is likely to be optimal in terms of fetal growth.  
 
<H1>Conclusion 
Our study suggests that control of gestational weight gain in women with GDM should be a 
priority to improve outcomes in terms of normalizing fetal growth and maximizing the 
chances of uncomplicated delivery. Furthermore, our results suggest that 28 weeks is not too 
late for women to benefit from limiting further gestational weight gain. In this study, women 
who maintained a stable weight after GDM diagnosis at 28 weeks had the best pregnancy 
outcomes for both mother and child. These findings suggest an urgent need to explore 
optimal methods of supporting weight control in women with GDM. 
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FIGURE 1 Use of antenatal data at booking, 28 and 36 weeks in order to assess total, early 
and late gestational weight gain. GWG, gestational weight gain; wk, week.  
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Table 1. Baseline characteristics of the study population  
 Gestational weight gain  
Outcomes Total (0–36 weeks) 
n = 376 
Early (0–28 weeks) 
n = 129 
Late (28–36 weeks) 
n = 144 
Total weight gain, kg  9.1 (5.1–13.1); 
median 8.9 
7.7 (4.0–11.2); 
median 7.8 
7.7 (4.0–11.2); 
median 7.8 
Total weight gain, % of pre-pregnancy 
weight 
13.3 (6.4–19.4); 
median 13.3 
10.8 (4.7–16.7); 
median 9.4 
10.8 (4.7–16.7); 
median 9.4 
Maternal BMI at booking, kg/m
2
 28.8 (23.4–32.7) 30.9 (24.01–36.4) 30.6 (23.7–36.2) 
Maternal age, years 34.0 (30.7 – 37.8) 34.3 (30.84 – 38.1) 34.0 (30.2 – 38.2) 
Estimated gestational age at GDM 
diagnosis, weeks 
28.1 (27.9–30.1); 
median 28.9 
24.5 (19.6–28.0); 
median 27.4 
24.7 (19.9–28.0); 
median 27.4 
Parity  0 164 (43.6) 46 (36.6) 51 (35.4) 
 1 131 (34.8) 42 (32.6) 47 (32.6) 
 ≥2 75 (19.9) 38 (29.5) 43 (29.9) 
 Unknown  6 (1.6) 2 (1.6) 3 (2.1) 
Mode of 
delivery  
Vaginal delivery (inc 
VBAC) 
167 (44.4) 57 (44.2) 66 (45.8) 
 Instrumental delivery 57 (15.2) 18 (14.0) 19 (13.2) 
 Caesarean delivery  152 (40.4) 54 (41.9) 58 (40.3) 
 Unknown  0 (0) 0 (0) 1 (0.7) 
Birthweight , g 3256 (2975–3535) 3151 (2880–3390) 3215 (2944–3475) 
Gestational age at delivery, weeks  38.6 (38.1–39.1) 38.2 (37.9–38.9) 38.4 (38.0–38.9) 
Large for gestational age 39 (10.4) 9 (7.0) 13 (9.2) 
Small for gestational age 28 (7.6) 10 (8.2) 10 (7.04) 
Fasting glucose at diagnosis, mmol/l 4.9 (4.3–5.3) 5.0 (4.4–5.5) 5.0 (4.4–5.4) 
Fasting glucose post-partum, mmol/l 4.7 (4.4–5.0) 4.8 (4.3–5.1) 4.8 (4.3–5.1) 
Treatment  Dietary management 
only 
176 (46.8) 46 (35.7) 54 (37.5) 
 Metformin only at 36 
weeks 
48 (12.8) 17 (13.2)   19 (13.2) 
 Insulin only at 36 
weeks 
108 (28.8) 39 (30.2) 40 (27.8) 
 Metformin and 
insulin at 36 weeks  
44 (11.7) 27 (20.9) 31 (21.5) 
Values are given as mean ± IQR or n (%). VBAC, vaginal birth after Caesarean. 
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Table 2. The effect of total gestational weight gain, early gestational weight gain and late gestational weight 
gain on pregnancy outcomes and treatment requirements in women with GDM  
 
 Gestational weight gain  
Outcomes Total (0–36 weeks) 
n = 376 
Early (0–28 weeks) 
n = 129 
Late (28–36 weeks) 
n = 144 
Categorical variables (logistic 
regression) 
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) 
Large for gestational age 1.08 (1.03 to 1.12)***  1.05 (0.94 to 1.16)  1.17 (1.01 to 1.37)*  
Small for gestational age 0.93 (0.87 to 0.99)*  0.89 (0.79 to 1.01)  1.03 (0.88 to 1.20)  
Vaginal delivery (including 
VBAC) 
0.94 (0.91 to 
0.97)***† 
0.97 (0.91 to 1.03)† 0.97 (0.87 to 1.08)† 
Caesarean delivery  1.05 (1.02 to 1.08)** † 1.06 (1.00 to 1.12)† 0.91 (0.80 to 1.02)† 
Instrumental delivery  1.01 (0.97 to 1.05)† 0.95 (0.88 to 1.03)† 1.26 (1.03 to 
1.55)**† 
Dietary management only at 36 
weeks 
1.00 (0.97 to 1.03) 1.00 (0.94 to 1.07) 1.03 (0.91 to 1.15) 
On Metformin at 36 weeks  0.98 (0.95 to 1.02) 0.98 (0.93 to 1.04) 0.95 (0.85 to 1.06) 
On Insulin at 36 weeks 1.01 (0.98 to 1.05) 1.02 (0.96 to 1.09) 1.01 (0.90 to 1.13) 
Continuous variables (linear 
regression) 
Beta coefficient (95% 
CI) 
Beta coefficient (95% 
CI) 
Beta coefficient 
(95% CI) 
Birthweight z score 0.02 (0.01 to 0.04)*** 0.02 (−0.01 to 0.04) 0.04 (< 0.01 to 0.08) 
Post-partum fasting glucose < 0.01 (−0.01 to 
< 0.01) 
−0.01 (−0.02 to 0.01) 0.03 (< 0.01 to 
0.07)* 
Post-partum 2-h OGTT glucose 0.01 (−0.01 to 0.03)‡ −0.02 (−0.07 to 0.04)‡ 0.12 (< 0.01 to 
0.22)*‡ 
Total daily insulin dose (36 weeks)  0.52 (0.01 to 1.03)*  1.20 (−0.19 to 2.60) 4.37 (1.92 to 
6.82)*** 
Total insulatard dose (36 weeks) 0.13 (−0.08 to 0.34) 0.21 (−0.25 to 0.67) 1.42 (0.62 to 
2.21)*** 
Total novorapid dose (36 weeks) 0.38 (−0.17 to 0.92) 0.81 (−0.63 to 2.25) 3.03 (0.07 to 6.00)*  
*P < 0.05, ** P < 0.01, *** P < 0.001. 
Odds ratio (95% CI) for categorical outcomes and beta coefficient (95% CI) for linear outcomes. Gestational 
weight gain categories were analysed as per cent change from pre-pregnancy/baseline weight and odds 
ratios/beta coefficients have been adjusted for antenatal fasting glucose (OGTT T0), parity and pre-pregnancy 
BMI, except where otherwise indicated (see below).  
†Delivery mode analyses adjusted for antenatal fasting glucose (OGTT T0), pre -pregnancy BMI, parity and 
birthweight z score. 
‡Post-partum 2-h OGTT g lucose concentration adjusted for antenatal 2-h OGTT g lucose, pre-pregnancy BMI 
and parity. 
OGTT, oral g lucose tolerance test; VBAC, vaginal birth after Caesarean. 
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Table 3. Outcomes for women with total gestational weight gain (n = 376) in categories, expressed as OR (95% CI).  
 Gestational weight gain  
 < 5% (n = 74) 5–15% (n = 152) > 15% (n = 150) 
Categorical variables (logistic regression) Odds ratios (95% CI)  Odds ratios (95% CI) Odds ratios (95% CI)  
Large for gestational age 0.30 (0.07 to 1.20)  1.00 (Referent) 2.83 (1.23 to 6.53)*  
Small for gestational age 2.43 (0.81 to 7.32)  1.00 (Referent) 0.55 (0.20 to 1.53)  
Vaginal delivery (including VBAC) 2.86 (1.47 to 5.57)**† 1.00 (Referent) 0.58 (0.34 to 1.00)* † 
Caesarean delivery  0.36 (0.18 to 0.74)**† 1.00 (Referent) 1.73 (1.02 to 2.92)* † 
Instrumental delivery (forceps or ventouse) 0.84 (0.29 to 2.44)† 1.00 (Referent) 0.98 (0.47 to 2.04)† 
Dietary management only at 36 weeks  1.05 (0.52 to 2.14)   1.00 (Referent) 1.23 (0.71 to 2.14)  
On metformin at 36 weeks  1.38 (0.70 to 2.70)  1.00 (Referent) 0.93 (0.50 to 1.72)  
On insulin at 36 weeks 0.66 (0.32 to 1.37)  1.00 (Referent) 0.92 (0.51 to 1.65)  
Continuous variables (linear regression) Beta coefficient (95% CI) Beta coefficient (95% CI) Beta coefficient (95% CI) 
Birthweight z score −0.12 (−0.40 to 0.15)  0.00 (Referent) 0.44 (0.22 to 0.67)***  
Post-partum fasting glucose −0.05 (−0.22 to 0.11)  0.00 (Referent) −0.13 (−0.26 to −0.01)*  
Post-partum 2-hour OGTT g lucose −0.30 (−0.82 to 0.21)‡ 0.00 (Referent) −0.03 (−0.43 to 0.36)‡ 
Total daily insulin dose (36w)  −6.25 (−16.51 to 4.02)  0.00 (Referent) 9.71 (1.05 to 18.37)*  
Total insulatard dose (36w) 0.39 (−3.95 to 4.72)  0.00 (Referent) 2.83 (−0.82 to 6.49)  
Total novorapid dose (36w) −6.40 (−17.30 to 4.50)  0.00 (Referent) 6.52 −1.53 to 14.58)  
*P < 0.05, **P <  0.01, ***P < 0.001. 
Models have all been adjusted for pre-pregnancy BMI, parity and antenatal fasting glucose except where otherwise indicated (see below). Models for modes of delivery have 
also been adjusted for birthweight z score, which takes account of gestational age and sex of the baby.  All models adjusted for antenatal fasting glucose (OGTT T0), p re-
pregnancy BMI and parity, unless otherwise indicated.  
†Delivery mode analyses adjusted for antenatal fasting glucose (OGTT T0), pre -pregnancy BMI, parity and birthweight z score. 
‡Post-partum 2-h OGTT g lucose concentration adjusted for antenatal 2-h OGTT g lucose, pre-pregnancy BMI and parity. 
VBAC, vaginal b irth after Caesarean. 
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Table 4. Assessment of the validity of IOM recommendations for gestational weight gain in women with by GDM and the min imum recommende d gestational weight gain of 
5 kg (n = 375; n = 1 missing height and therefore BMI)  
(a) Assessing the validity of  the IOM recommendations 
 Gained below IOM 
recommendations (n = 167) 
Gained according to IOM 
recommendations (n = 111) 
Gained above IOM 
recommendations (n = 97) 
Categorical variables (logistic 
regression) 
Odds ratios (95% CI) Odds ratios (95% CI) Odds ratios (95% CI) 
Large for gestational age 0.43 (0.17 to 1.08) 1.00 (Referent) 1.57 (0.69 to 3.57) 
Small for gestational age 6.85 (1.54 to 30.47)*  1.00 (Referent) 4.14 (0.81 to 21.29) 
Vaginal delivery (including 
VBAC) 
1.06 (0.63 to 1.79)† 1.00 (Referent) 0.46 (0.25 to 0.86)* † 
Caesarean delivery  0.76 (0.45 to 1.29)† 1.00 (Referent) 1.87 (1.05 to 3.34)* † 
Instrumental delivery  1.63 (0.75 to 3.52)† 1.00 (Referent) 1.20 (0.48 to 2.98)† 
Dietary management only at 36 
weeks 
1.41 (0.80 to 2.46) 1.00 (Referent) 1.11 (0.58 to 2.12) 
On Metformin at 36 weeks  0.77 (0.43 to 1.38) 1.00 (Referent) 0.63 (0.32 to 1.24) 
On Insulin at 36 weeks 0.85 (0.47 to 1.55) 1.00 (Referent) 1.54 (0.81 to 2.96) 
Continuous variables (linear 
regression) 
Beta coefficient (95% CI) Beta coefficient (95% CI) Beta coefficient (95% CI) 
Birthweight (g) −0.28 (−0.51 to −0.05)*  0.00 (Referent) 0.06 (−0.02 to 0.32) 
Postnatal fasting glucose 0.03 (−0.09 to 0.16) 0.00 (Referent) < 0.01 (−0.15 to 0.15) 
Post-partum 2-h OGTT glucose 0.05 (−0.34 to 0.44)‡ 0.00 (Referent) 0.19 (−0.26 to 0.63)‡ 
Total daily insulin dose (36w)  −1.50 (−10.68 to 7.67) 0.00 (Referent) 9.08 (−0.36 to 18.51) 
Total insulatard dose (36w) 2.30 (−1.50 to 6.10) 0.00 (Referent) 5.05 (1.15 to 8.96)*  
Total novorapid dose (36w) −3.23 (−11.83 to 5.37) 0.00 (Referent) 6.34 (−2.54 to 15.23) 
(b) Assessing the validity of the recommended 5kg minimum weight gain, regardless of pre-pregnancy BMI 
 Gained < 5 kg (n = 91) All other women (n = 285) 
Categorical variables (logistic regression) Odds ratios (95% CI) Odds ratios (95% CI) 
Large for gestational age 0.18 (0.05 to 0.64)**  1.00 (Referent) 
Small for gestational age 2.27 (0.86 to 6.00) 1.00 (Referent) 
Vaginal delivery (including VBAC) 1.94 (1.11 to 3.38)* † 1.00 (Referent) 
Caesarean delivery  0.53 (0.30 to 0.95)* † 1.00 (Referent) 
Instrumental delivery  1.00 (0.42 to 2.39)† 1.00 (Referent) 
Dietary management only at 36 weeks 1.18 (0.64 to 2.17) 1.00 (Referent) 
On metformin at 36 weeks  1.31 (0.72 to 2.38) 1.00 (Referent) 
On insulin at 36 weeks 0.63 (0.33 to 1.19) 1.00 (Referent) 
Continuous variables (linear regression) Beta coefficient (95% CI) Beta coefficient (95% CI) 
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Birthweight z score −0.34 (−0.58 to −0.10)** 0.00 (Referent) 
Post-partum fasting glucose 0.10 (−0.04 to 0.23) 0.00 (Referent) 
Post-partum 2-h OGTT glucose −0.07 (−0.50 to 0.36)‡ 0.00 (Referent) 
Total daily insulin dose (36 weeks)  −8.09 (−17.26 to 1.08) 0.00 (Referent) 
Total insulatard dose (36 weeks) −0.48 (−4.32 to 3.35) 0.00 (Referent) 
Total novorapid dose (36 weeks) −6.34 (−15.91 to 3.22) 0.00 (Referent) 
*P < 0.05, **P <  0.01, ***P < 0.001. 
Outcomes were expressed as OR (95% CI). The Institute of Medicine (IOM) recommendations state that normal weight, overweight and obese women are advised to gain 
11.4–15.9 kg, 6.8–11.4 kg and 5.0–9.1 kg respectively [29]. Models have all been adjusted for pre-pregnancy BMI, antenatal fasting glucose and parity except where 
otherwise indicated (see below).  
All models adjusted for antenatal fasting glucose (OGTT T0), p re-pregnancy BMI and parity, unless otherwise indicated 
†Adjusted for antenatal fasting glucose (OGTT T0), pre-pregnancy BMI and birthweight z score 
‡Adjusted for antenatal 120-min glucose (OGTT T120) and pre-pregnancy BMI. 
VBAC, vaginal b irth after Caesarean
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